Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation

The use of post-transplantation cyclophosphamide (PTCy) has overcome historical barriers to hematopoietic cell transplantation (HCT) by safely facilitating human leukocyte antigen (HLA)-haploidentical HCT and by reducing rates of severe acute and particularly chronic graft-versus-host disease (GVHD). [1] The clinical implementation of PTCy was based on studies in major histocompatibility complex (MHC)-matched skin allografting models, which suggested that a high 200 mg/kg dose of PTCy on day +2 or +3 after donor splenocyte infusion was effective in prolonging survival of a subsequently placed skin allograft; lower doses or administration at earlier or later times were less effective or ineffective.

Source: Biology of Blood and Marrow Transplantation - October 1, 2019 Category: Hematology Authors: Lucas P. Wachsmuth, Michael T. Patterson, Michael A. Eckhaus, David J. Venzon, Christopher G. Kanakry Source Type: research